Tuberculosis Therapeutics Market - By Disease Type (Active TB, Latent TB), Therapy (First-Line Therapy, Second-Line Therapy), Route of Administration (Oral, Parenteral), Dosage Form (Tablets, Capsules), Distribution Channel & Forecast, 2024 – 2032

Tuberculosis Therapeutics Market - By Disease Type (Active TB, Latent TB), Therapy (First-Line Therapy, Second-Line Therapy), Route of Administration (Oral, Parenteral), Dosage Form (Tablets, Capsules), Distribution Channel & Forecast, 2024 – 2032

Tuberculosis Therapeutics Market Size

Tuberculosis Therapeutics Market size was valued at around USD 2 billion in 2023 and is estimated to grow at 4.1% CAGR from 2024 to 2032. The rising prevalence of Tuberculosis (TB) globally is a significant driver for the growth of the market. TB remains a major global health threat, with a high burden in many parts of the world, particularly in developing countries and regions with high population density and limited healthcare access.

For instance, according to the World Health Organization (WHO), in 2020, an estimated 10 million people fell ill with TB globally. This number includes 5.6 million men, 3.2 million women, and 1.2 million children. This demonstrates a persistently high level of TB incidence, despite efforts to control the disease. Ongoing investments in research, development, and public health initiatives are crucial in addressing the challenges posed by TB and advancing treatment options to improve outcomes for patients worldwide.  
 

What are the growth opportunities in this market?

 Download Free Sample

Tuberculosis (TB) therapeutics refer to the range of medical treatments and interventions aimed at combating Tuberculosis infections, caused primarily by Mycobacterium Tuberculosis bacteria. TB is a contagious airborne disease that primarily affects the lungs but can also impact other parts of the body.

Tuberculosis Therapeutics Market Trends

Recent advancements in Tuberculosis (TB) therapeutics have contributed significantly to the growth and development of the TB therapeutics market.  

• The introduction of shorter treatment regimens for drug-sensitive TB has been a significant advancement. These regimens typically involve a combination of rifapentine and isoniazid, administered once weekly for 3 months followed by 4 months of rifampicin and isoniazid.
• Research is ongoing into therapeutic vaccines that could potentially enhance the immune response against Tuberculosis, aiding in treatment outcomes and reducing disease severity. Drugs that modulate the host immune response to improve TB treatment outcomes are also under investigation.
• Continued research into optimal drug combinations, including new and existing drugs, to improve treatment efficacy, shorten duration, and reduce the emergence of drug resistance.
• Rapid molecular diagnostic tests such as GeneXpert MTB/RIF have revolutionized TB diagnosis by detecting TB and rifampicin resistance within hours, enabling early initiation of appropriate treatment.
• As these innovations translate into clinical practice, they are expected to drive continued growth in the global market for Tuberculosis therapeutics.

Tuberculosis Therapeutics Market Analysis

Based on disease type, the market is categorized into active TB, and latent TB. The active TB segment dominated the market, with a revenue share of around 88.8% in 2023.

• Active TB is contagious and poses a significant public health threat. It requires immediate and effective treatment to prevent the spread of the disease, making it a priority for public health interventions and resource allocation.
• Additionally, active TB is more likely to be detected and diagnosed due to its symptomatic nature, leading to a higher number of identified and treated cases compared to latent TB, which is often asymptomatic and can remain undiagnosed.

Based on therapy, the tuberculosis therapeutics market is categorized into first-line therapy and second-line therapy. The first-line therapy segment dominated the market with a revenue of USD 1.2 billion in 2023.

• First-line therapies are used to treat the majority of TB patients, especially those with drug-sensitive TB. This encompasses a large portion of TB cases globally, driving the higher volume and dominance of first-line therapy in the market.
• Additionally, first-line TB drugs are generally more affordable than second-line drugs, making them more accessible, particularly in low- and middle-income countries where TB burden is high. This cost-effectiveness contributes to their widespread use and market dominance.

Based on route of administration, the tuberculosis therapeutics market is categorized into oral, parenteral, and other route of administration. The oral segment is anticipated to dominate the market, with a revenue of around USD 2 billion in 2032.

• Oral medications are easier to administer and more convenient for patients compared to parenteral routes. This convenience enhances patient compliance, which is crucial for the lengthy TB treatment regimen.
• Additionally, oral TB drugs are widely available and can be distributed easily across various healthcare settings, including remote and low-resource areas. This widespread availability supports their dominance in the market.

Based on dosage form, the tuberculosis therapeutics market is categorized into tablets, capsules, injection, and other dosage forms. The tablet segment is anticipated to dominate the market with USD 1.7 billion in 2032.

• Tablets are easy to administer, which improves patient compliance, especially important for the lengthy TB treatment regimen. Patients are more likely to adhere to a treatment plan that involves simply taking tablets daily.
   
• Additionally, many TB treatment regimens involve fixed-dose combination tablets, which include multiple anti-TB drugs in a single tablet. This simplifies the treatment regimen, reduces pill burden, and improves adherence.

Based on distribution channel, the tuberculosis therapeutics market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market, with a revenue share of around 69.4% in 2023.

• Hospital pharmacies are directly integrated into healthcare facilities where TB patients are diagnosed and treated. This ensures immediate access to TB medications as part of the comprehensive care provided in hospitals.
• Additionally, hospitals provide comprehensive tuberculosis diagnostics tests and monitoring facilities, which are essential for managing TB treatment and adjusting regimens based on patient response. Hospital pharmacies are integral to this process, providing timely access to necessary medications.

North America tuberculosis therapeutics market accounted for USD 642.6 million revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.

• Robust public health programs and initiatives by government agencies such as the Centers for Disease Control and Prevention (CDC) in the U.S. and Public Health Agency of Canada focus on TB prevention, diagnosis, and treatment. These programs ensure access to TB therapeutics and support research into new treatments.
• These government funding and support for TB research, including clinical trials for new drugs and treatment regimens, contribute to advancements in TB therapeutics in North America.

U.S. tuberculosis therapeutics market holds a dominant position with the market share of 94.6% in 2023.

• The U.S. National TB Elimination Plan focuses on reducing TB incidence and addressing disparities in TB burden, fostering a conducive environment for TB therapeutic development and deployment.
• Additionally, dedicated TB clinics and healthcare facilities equipped with advanced diagnostic tools, such as molecular tests and radiographic imaging, support timely diagnosis and treatment initiation.

Germany Tuberculosis therapeutics market is expected to grow significantly during the forecast period.

• Germany is home to leading academic and research institutions that conduct cutting-edge research on TB. These institutions collaborate with pharmaceutical companies and international partners to develop new drugs, vaccines, and diagnostic tools for TB therapeutics.
• Additionally, Germany participates in multinational clinical trials to evaluate the safety and efficacy of novel TB therapies, contributing to advancements in TB treatment options.

China Tuberculosis therapeutics market is anticipated to witness a high growth rate from 2024-2032, due to several factors.

• China's efforts to expand healthcare infrastructure, particularly in rural and underserved areas, enhance access to TB diagnosis and treatment services.
• Additionally, community health centers and TB dispensaries play a crucial role in decentralized TB care delivery, ensuring continuity of treatment and patient adherence.

Tuberculosis Therapeutics Market Share

The Tuberculosis therapeutics industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel therapeutics with improved efficiency and cost-effectiveness are key market strategies for Tuberculosis therapeutics, drugs manufacturers, driving competition and innovation in the industry. This emphasis on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain market share and meet the growing demand for novel Tuberculosis therapeutics.

Tuberculosis Therapeutics Market Companies

Some of the eminent market participants operating in the Tuberculosis therapeutics industry include

• Aventis Pharmaceuticals Limited
• Bayer Health Care
• Eli Lilly And Company
• Johnson & Johnson Services; Inc.
• Lupin
• Macleods Pharmaceuticals Ltd.
• Mylan N.V.
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sanofi

Tuberculosis Therapeutics Industry News

• In September 2021, Lupin Limited received the grant from TB Alliance to non-exclusive license to manufacture the anti-TB drug Pretomanid as part of the three-drug “BPaL” regimen. This approval enhanced the company’s market positioning in Tuberculosis therapeutic market and expanded its customer base.  
• In November 2023, Indian pharmaceutical company Macleods become the second manufacturer to launch Pretomanid, a treatment regimen for drug-resistant Tuberculosis (DR-TB). This launch expanded the company’s market presence and generated revenue for the company.

Tuberculosis therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments

Click here to Buy Section of this Report

Market, By Disease Type

• Active TB
• Latent TB

Market, By Therapy

• First-line therapy
• Second-line therapy

Market, By Route of Administration

• Oral
• Parenteral
• Other route of administration

Market, By Dosage Form

• Tablets
• Capsules
• Injection
• Other dosage forms

Market, By Distribution Channel      

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa